A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas

CD30 is a 120‐kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large‐cell lymphoma (ALCL). CD30‐targeted treatment with antibody–drug conjugates (ADCs) can lead t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rong, Li, Liang, Zhang, Shenghua, Li, Yi, Wang, Xiaofei, Miao, Qingfang, Zhen, Yongsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830626/
https://www.ncbi.nlm.nih.gov/pubmed/29316337
http://dx.doi.org/10.1002/1878-0261.12166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830626/
https://www.ncbi.nlm.nih.gov/pubmed/29316337
http://dx.doi.org/10.1002/1878-0261.12166

Ejemplares similares